|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
9
|
|
pubmed:dateCreated |
2011-3-9
|
|
pubmed:abstractText |
Trastuzumab is a recombinant antibody drug that is widely used for the treatment of HER2-overexpressing breast carcinoma. Despite encouraging clinical results, many HER2-overexpressing carcinomas are primarily resistant to trastuzumab. We attempted to explain trastuzumab resistance and search for solutions. Since the killer cell lectin-like receptor G1 (KLRG1), an inhibitory receptor expressed on subsets of natural killer (NK) cells recognizes E-cadherin as ligands and may inhibit immune responses by regulating the effector function of NK cells, we used HER2-overexpressing carcinoma cells which were expressing E-cadherin to investigate the role of antibody-dependent cellular cytotoxicity (ADCC) through KLRG1 on NK cells in vitro and vivo. The results indicated that HER2-overexpressing carcinoma cells were killed by trastuzumab-mediated ADCC and the ADCC activity was reflected the degree of E-cadherin expression on carcinoma cells. We found that expression of E-cadherin was shown to be a predictor of response to trastuzumab-based treatment for HER2-overexpressing carcinomas, furthermore, trastuzumab-mediated ADCC was markedly enhanced by KLRG1-negative peripheral blood mononuclear cells (PBMCs(KLRG1(-))).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, Humanized,
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Cadherins,
http://linkedlifedata.com/resource/pubmed/chemical/KLRG1 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Lectins, C-Type,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor, erbB-2,
http://linkedlifedata.com/resource/pubmed/chemical/Trans-Activators,
http://linkedlifedata.com/resource/pubmed/chemical/trastuzumab
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
1097-0215
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright © 2011 UICC.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
1
|
|
pubmed:volume |
128
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2125-37
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:21387286-Animals,
pubmed-meshheading:21387286-Antibodies, Monoclonal,
pubmed-meshheading:21387286-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:21387286-Antibody-Dependent Cell Cytotoxicity,
pubmed-meshheading:21387286-Antineoplastic Agents,
pubmed-meshheading:21387286-Breast Neoplasms,
pubmed-meshheading:21387286-Cadherins,
pubmed-meshheading:21387286-Cell Line, Tumor,
pubmed-meshheading:21387286-Drug Resistance, Neoplasm,
pubmed-meshheading:21387286-Female,
pubmed-meshheading:21387286-Humans,
pubmed-meshheading:21387286-Immunohistochemistry,
pubmed-meshheading:21387286-Killer Cells, Natural,
pubmed-meshheading:21387286-Lectins, C-Type,
pubmed-meshheading:21387286-Mice,
pubmed-meshheading:21387286-Mice, Inbred NOD,
pubmed-meshheading:21387286-Mice, SCID,
pubmed-meshheading:21387286-Receptor, erbB-2,
pubmed-meshheading:21387286-Trans-Activators,
pubmed-meshheading:21387286-Xenograft Model Antitumor Assays
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
E-cadherin expression on human carcinoma cell affects trastuzumab-mediated antibody-dependent cellular cytotoxicity through killer cell lectin-like receptor G1 on natural killer cells.
|
|
pubmed:affiliation |
Pathology Division, Research Center for Innovative Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
